HSP27 Reduces Herceptin Effectiveness in Breast Cancer
Author Information
Author(s): Kang Se Hun, Kang Keon Wook, Kim Kyung-Hee, Kwon Bumi, Kim Seok-Ki, Lee Ho-Young, Kong Sun-Young, Lee Eun Sook, Jang Sang-Geun, Yoo Byong Chul
Primary Institution: National Cancer Center, Republic of Korea
Hypothesis
Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stability.
Conclusion
The study shows that higher levels of HSP27 in breast cancer cells make them less responsive to Herceptin by stabilizing Her2 protein.
Supporting Evidence
- HSP27 expression was upregulated in Herceptin-resistant SK-BR-3 HR cells.
- Suppression of HSP27 increased the susceptibility of SK-BR-3 HR cells to Herceptin.
- Her2 expression was reduced more in SK-BR-3 parent cells than in SK-BR-3 HR cells when treated with Herceptin.
- HSP27 can bind to Her2, indicating a potential mechanism for Her2 stability.
- Downregulation of Her2 by Herceptin can be obstructed by the formation of a Her2-HSP27 complex.
Takeaway
This study found that a protein called HSP27 helps cancer cells resist a treatment called Herceptin, making it harder for the treatment to work.
Methodology
The study used comparative proteome approaches to analyze two human breast cancer cell lines, SK-BR-3 and its Herceptin-resistant derivative SK-BR-3 HR.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website